Your session is about to expire
Summary
This is an intermediate-size expanded access protocol to provide ONC201 (dordaviprone) to patients with H3 K27M-mutant and/or midline gliomas who cannot access ONC201 (dordaviprone) through clinical trials.
Eligible Conditions
- Mesial Temporal Sclerosis
- Brain Tumor
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Find a Location
Who is running the clinical trial?
ChimerixLead Sponsor
41 Previous Clinical Trials
4,087 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger